0001474064-13-000062.txt : 20130410
0001474064-13-000062.hdr.sgml : 20130410
20130410181845
ACCESSION NUMBER: 0001474064-13-000062
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130409
FILED AS OF DATE: 20130410
DATE AS OF CHANGE: 20130410
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rogus Joseph J
CENTRAL INDEX KEY: 0001299691
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23272
FILM NUMBER: 13754639
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
STREET 2: 3RD FLOOR
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000890465
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 870439579
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
BUSINESS PHONE: (908) 450-5300
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2013-04-09
0000890465
NPS PHARMACEUTICALS INC
NPSP
0001299691
Rogus Joseph J
550 HILLS DRIVE
BEDMINSTER
NJ
07921
0
1
0
0
VP, Technical Operations
Common Stock
2013-04-09
4
M
0
5175
5.85
A
24547
D
Common Stock
2013-04-09
4
M
0
7374
5.71
A
31921
D
Common Stock
2013-04-09
4
M
0
25396
5.71
A
57317
D
Common Stock
2013-04-09
4
M
0
7195
3.34
A
64512
D
Common Stock
2013-04-09
4
M
0
2875
3.34
A
67387
D
Common Stock
2013-04-09
4
S
0
48015
11.50
D
19372
D
Stock Option
5.85
2013-04-09
4
M
0
5175
0
D
2018-10-15
Common Stock
5175
0
D
Stock Option
5.71
2013-04-09
4
M
0
7374
0
D
2019-01-20
Common Stock
7374
0
D
Stock Option
5.71
2013-04-09
4
M
0
25396
0
D
2019-01-20
Common Stock
25396
0
D
Stock Option
3.34
2013-04-09
4
M
0
7195
0
D
2020-02-19
Common Stock
7195
0
D
Stock Option
3.34
2013-04-09
4
M
0
2875
0
D
2020-02-19
Common Stock
2875
0
D
The shares were sold pursuant to a predefined price target in a trading plan qualified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, that was effective December 6, 2012.
On October 15, 2008, the Reporting Person received a grant of 5,175 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the date of grant and 2% each month for the next three years.
On January 20, 2009, the Reporting Person received a grant of 7,374 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter.
On January 20, 2009, the Reporting Person received a grant of 25,396 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter.
On February 19, 2010, the Reporting Person received a grant of 7,195 stock options under the Issuer's 2005 Omnibus Incentive Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter.
On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. On February 17, 2011, the performance criteria for 11,500 of these options had been satisfied because the Issuer's Phase 3 pivotal study of GATTEX (teduglutide) had met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome. These 11,500 options will vest and become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.
/s/ Joseph Rogus, by Edward Stratemeier as attorney-in-fact
2013-04-09